NCT01084538 - Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis | Biotech Hunter

Enrollment

181

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Parathyroid Hormone

Interventions

DRUG

Zemplar iv (paricalcitol iv)

Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.

Trial Locations (21)

1000

Site Reference ID/Investigator# 27530, Split

10000

Site Reference ID/Investigator# 27526, Zagreb

Site Reference ID/Investigator# 27532, Zagreb

11000

Site Reference ID/Investigator# 27536, Belgrade

Site Reference ID/Investigator# 27538, Belgrade

Site Reference ID/Investigator# 27539, Belgrade

Site Reference ID/Investigator# 6169, Belgrade

11080

Site Reference ID/Investigator# 27540, Belgrade

19210

Site Reference ID/Investigator# 27535, Bor

20000

Site Reference ID/Investigator# 27525, Dubrovnik

21220

Site Reference ID/Investigator# 27534, Trogir

21260

Site Reference ID/Investigator# 27531, Imotski

22000

Site Reference ID/Investigator# 27524, Šibenik

23000

Site Reference ID/Investigator# 27527, Zadar

32000

Site Reference ID/Investigator# 27522, Vinkovci

34000

Site Reference ID/Investigator# 27537, Kragujevac

35000

Site Reference ID/Investigator# 27529, Slavonski Brod

44000

Site Reference ID/Investigator# 27523, Sisak

47000

Site Reference ID/Investigator# 6175, Karlovac

51000

Site Reference ID/Investigator# 27533, Rijeka

52100

Site Reference ID/Investigator# 27528, Pula